62 research outputs found
Survival outcomes and mobilization during venovenous extracorporeal membrane oxygenation: a retrospective cohort study
IntroductionVenovenous extracorporeal membrane oxygenation (V-V ECMO) can be considered in critically ill patient in severe pulmonary failure. However, the mobilization of patients on V-V ECMO can be challenging due to logistic and safety concerns. This study aimed to investigate whether 30âdays survival was improved in patients who were mobilized during V-V ECMO support.MethodsWe conducted a retrospective cohort all-comer study that included all patients cannulated for V-V ECMO at a single center. Patients with a V-V ECMO duration below 24âh were excluded from the analysis. The patients were grouped based on the ICU mobility scale documented during V-V ECMO support. The primary endpoint was 30âdays survival, and secondary endpoints included weaning from ECMO and mechanical ventilation, as well as hospital survival.ResultsA total of 343 patients were included in the study, with a median age of 56âyears and 32% were female. Among them, 28% had chronic lung disease. The ICU mobilization scale â„2 during ECMO was documented in 62/343 (18%) patients. There were no significant differences in age, gender and preexisting lung disease. Duration of ICU stay (13.1 vs. 15.6âdays), time on ECMO (186 vs. 190âh) and mechanical ventilation (11.2 vs. 13.6âdays) were slightly shorter in patients with ICU mobility scale <2 compared to those with â„2 (all pâ=â0.0001). However, patients with ICU mobilization scale â„2 showed significantly better 30âdays survival (71.0 vs. 48.0%, OR 2.6 (1.5 to 4.8), pâ=â0.0012) compared to those with <2. In the â„2 mobility scale group, a significantly higher number of patients were successfully weaned from the ventilator (61.3 vs. 46.6%, OR 1.8 (1.0 to 3.2), pâ=â0.049). A stronger correlation was observed between more intense mobilizations, such as being in a standing position (OR 5.0 (1.7 to 14.0), pâ=â0.0038), and higher 30âdays survival.ConclusionThe findings of this study suggest that active mobilization during V-V ECMO support is associated with improved 30âdays survival and successful weaning from the respirator. Incorporating mobilization as part of the therapeutic approach during ECMO support may offer potential benefits for critically ill patients
Clinical scenarios for use of transvalvular microaxial pumps in acute heart failure and cardiogenic shock â A European experienced users working group opinion
Abstract For patients with myocardial infarct-related cardiogenic shock (CS), urgent percutaneous coronary intervention is the recommended treatment strategy to limit cardiac and systemic ischemia. However, a specific therapeutic intervention is often missing in non-ischemic CS cases. Though drug treatment with inotropes and/or vasopressors may be required to stabilize the patient initially, their ongoing use is associated with excess mortality. Coronary intervention in unstable patients often leads to further hemodynamic compromise either during or shortly after revascularization. Support devices like the intra-aortic balloon pump failed to improve clinical outcomes in infarct-related CS. Currently, more powerful and active hemodynamic support devices unloading the left ventricle such as transvalvular microaxial pumps are available and are being increasingly used. However, as for other devices large randomized trials are not yet available, and device use is based on registry data and expert consensus. In this article, a multidisciplinary group of experienced users of transvalvular microaxial pumps outlines the pathophysiological background on hemodynamic changes in CS, the available mechanical support devices, and current guideline recommendations. Furthermore, different hemodynamic situations in several case-based scenarios are used to illustrate candidate settings and to provide the theoretic and scientific rationale for left-ventricular unloading in these scenarios. Finally, organization of shock networks, monitoring, weaning, and typical complications and their prevention are discussed
Treatment of Refractory Cardiac Arrest by Controlled Reperfusion of the Whole Body:A Multicenter, Prospective Observational Study
Background: Survival following cardiac arrest (CA) remains poor after conventional cardiopulmonary resuscitation (CCPR) (6â26%), and the outcomes after extracorporeal cardiopulmonary resuscitation (ECPR) are often inconsistent. Poor survival is a consequence of CA, low-flow states during CCPR, multi-organ injury, insufficient monitoring, and delayed treatment of the causative condition. We developed a new strategy to address these issues. Methods: This all-comers, multicenter, prospective observational study (69 patients with in- and out-of-hospital CA (IHCA and OHCA) after prolonged refractory CCPR) focused on extracorporeal cardiopulmonary support, comprehensive monitoring, multi-organ repair, and the potential for out-of-hospital cannulation and treatment. Result: The overall survival rate at hospital discharge was 42.0%, and a favorable neurological outcome (CPC 1+2) at 90 days was achieved for 79.3% of survivors (CPC 1+2 survival 33%). IHCA survival was very favorable (51.7%), as was CPC 1+2 survival at 90 days (41%). Survival of OHCA patients was 35% and CPC 1+2 survival at 90 days was 28%. The subgroup of OHCA patients with pre-hospital cannulation showed a superior survival rate of 57.1%. Conclusions: This new strategy focusing on repairing damage to multiple organs appears to improve outcomes after CA, and these findings should provide a sound basis for further research in this area.</p
Treatment of Refractory Cardiac Arrest by Controlled Reperfusion of the Whole Body:A Multicenter, Prospective Observational Study
Background: Survival following cardiac arrest (CA) remains poor after conventional cardiopulmonary resuscitation (CCPR) (6â26%), and the outcomes after extracorporeal cardiopulmonary resuscitation (ECPR) are often inconsistent. Poor survival is a consequence of CA, low-flow states during CCPR, multi-organ injury, insufficient monitoring, and delayed treatment of the causative condition. We developed a new strategy to address these issues. Methods: This all-comers, multicenter, prospective observational study (69 patients with in- and out-of-hospital CA (IHCA and OHCA) after prolonged refractory CCPR) focused on extracorporeal cardiopulmonary support, comprehensive monitoring, multi-organ repair, and the potential for out-of-hospital cannulation and treatment. Result: The overall survival rate at hospital discharge was 42.0%, and a favorable neurological outcome (CPC 1+2) at 90 days was achieved for 79.3% of survivors (CPC 1+2 survival 33%). IHCA survival was very favorable (51.7%), as was CPC 1+2 survival at 90 days (41%). Survival of OHCA patients was 35% and CPC 1+2 survival at 90 days was 28%. The subgroup of OHCA patients with pre-hospital cannulation showed a superior survival rate of 57.1%. Conclusions: This new strategy focusing on repairing damage to multiple organs appears to improve outcomes after CA, and these findings should provide a sound basis for further research in this area.</p
Outcome Prediction in Patients with Severe COVID-19 Requiring Extracorporeal Membrane OxygenationâA Retrospective International Multicenter Study
The role of veno-venous extracorporeal membrane oxygenation therapy (V-V ECMO) in
severe COVID-19 acute respiratory distress syndrome (ARDS) is still under debate and conclusive
data from large cohorts are scarce. Furthermore, criteria for the selection of patients that benefit most
from this highly invasive and resource-demanding therapy are yet to be defined. In this study, we
assess survival in an international multicenter cohort of COVID-19 patients treated with V-V ECMO
and evaluate the performance of several clinical scores to predict 30-day survival. Methods: This is
an investigator-initiated retrospective non-interventional international multicenter registry study
(NCT04405973, first registered 28 May 2020). In 127 patients treated with V-V ECMO at 15 centers in
Germany, Switzerland, Italy, Belgium, and the United States, we calculated the Sequential Organ
Failure Assessment (SOFA) Score, Simplified Acute Physiology Score II (SAPS II), Acute Physiology And Chronic Health Evaluation II (APACHE II) Score, Respiratory Extracorporeal Membrane
Oxygenation Survival Prediction (RESP) Score, Predicting Death for Severe ARDS on V-V ECMO
(PRESERVE) Score, and 30-day survival. Results: In our study cohort which enrolled 127 patients,
overall 30-day survival was 54%. Median SOFA, SAPS II, APACHE II, RESP, and PRESERVE were 9,
36, 17, 1, and 4, respectively. The prognostic accuracy for all these scores (area under the receiver
operating characteristicâAUROC) ranged between 0.548 and 0.605. Conclusions: The use of scores
for the prediction of mortality cannot be recommended for treatment decisions in severe COVID-19
ARDS undergoing V-V ECMO; nevertheless, scoring results below or above a specific cut-off value
may be considered as an additional tool in the evaluation of prognosis. Survival rates in this cohort of
COVID-19 patients treated with V-V ECMO were slightly lower than those reported in non-COVID-19
ARDS patients treated with V-V ECMO
Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort
ECMO for COVID-19 patients in Europe and Israel
Since March 15th, 2020, 177 centres from Europe and Israel have joined the study, routinely reporting on the ECMO support they provide to COVID-19 patients. The mean annual number of cases treated with ECMO in the participating centres before the pandemic (2019) was 55. The number of COVID-19 patients has increased rapidly each week reaching 1531 treated patients as of September 14th. The greatest number of cases has been reported from France (n = 385), UK (n = 193), Germany (n = 176), Spain (n = 166), and Italy (n = 136) .The mean age of treated patients was 52.6 years (range 16â80), 79% were male. The ECMO configuration used was VV in 91% of cases, VA in 5% and other in 4%. The mean PaO2 before ECMO implantation was 65 mmHg. The mean duration of ECMO support thus far has been 18 days and the mean ICU length of stay of these patients was 33 days. As of the 14th September, overall 841 patients have been weaned from ECMO
support, 601 died during ECMO support, 71 died after withdrawal of ECMO, 79 are still receiving ECMO support and for 10 patients status n.a. . Our preliminary data suggest that patients placed
on ECMO with severe refractory respiratory or cardiac failure secondary to COVID-19 have a reasonable (55%) chance of survival. Further extensive data analysis is expected to provide invaluable information on the demographics, severity of illness, indications and different ECMO management strategies in these patients
Beta-blockers in refractory hypoxemia on venovenous extracorporeal membrane oxygenation: a double-edged sword
- âŠ